keyword
MENU ▼
Read by QxMD icon Read
search

Soliris

keyword
https://www.readbyqxmd.com/read/29435915/eculizumab-a-review-in-generalized-myasthenia-gravis
#1
Sohita Dhillon
The humanized monoclonal antibody eculizumab (Soliris® ) is a complement inhibitor indicated for use in anti-acetylcholine receptor (AChR) antibody-positive adults with generalized myasthenia gravis (gMG) in the USA, refractory gMG in the EU, or gMG with symptoms that are difficult to control with high-dose IVIg therapy or PLEX in Japan. It is the first complement inhibitor to be approved for use in these patients. In the well-designed, 26-week REGAIN study in patients with anti-AChR-positive refractory gMG, although a statistically significant benefit of eculizumab over placebo in the prespecified primary endpoint analysis (change from baseline in MG-activities of daily living (ADL) score assessed by worst-rank ANCOVA) was not formally demonstrated, preplanned and post hoc sensitivity analyses of this outcome, as well as other secondary outcomes supported the efficacy of eculizumab...
March 2018: Drugs
https://www.readbyqxmd.com/read/29337452/-neurology
#2
Isabelle Chopard, David Benninger, Jean-François Demonet, Renaud Du Pasquier, Lorenz Hirt, Thierry Kuntzer, Patrik Michel, Bernard Nater, Jan Novy, Andrea Rossetti, Olivier Rouaud, Philippe Ryvlin, Myriam Schluep, Marie Theaudin
Ocrelizumab (Ocrevus), an anti-CD20 monoclonal antibody, has been approved for the treatment of multiple sclerosis. Eculizumab (Soliris) has been approved in several countries for refractory forms of generalized seropositive severe myasthenia gravis. A form of gene therapy, patisiran, has shown positive results in transthyretin familial amyloidosis. In the treatment of headaches, particularly migraines, non-pharmacological approaches have shown some interesting results. The criteria for Lewy body dementia have been revised...
January 10, 2018: Revue Médicale Suisse
https://www.readbyqxmd.com/read/28846836/high-risk-for-invasive-meningococcal-disease-among-patients-receiving-eculizumab-soliris-despite-receipt-of-meningococcal-vaccine
#3
EDITORIAL
L A McNamara, N Topaz, X Wang, S Hariri, L Fox, J R MacNeil
No abstract text is available yet for this article.
September 2017: American Journal of Transplantation
https://www.readbyqxmd.com/read/28704351/high-risk-for-invasive-meningococcal-disease-among-patients-receiving-eculizumab-soliris-despite-receipt-of-meningococcal-vaccine
#4
Lucy A McNamara, Nadav Topaz, Xin Wang, Susan Hariri, LeAnne Fox, Jessica R MacNeil
Use of eculizumab (Soliris, Alexion Pharmaceuticals), a terminal complement inhibitor, is associated with a 1,000-fold to 2,000-fold increased incidence of meningococcal disease (1). Administration of meningococcal vaccines is recommended for patients receiving eculizumab before beginning treatment (2,3). Sixteen cases of meningococcal disease were identified in eculizumab recipients in the United States during 2008-2016; among these, 11 were caused by nongroupable Neisseria meningitidis. Fourteen patients had documentation of receipt of at least 1 dose of meningococcal vaccine before disease onset...
July 14, 2017: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/28400215/levamisole-enhances-the-innate-immune-response-and-prevents-increased-cortisol-levels-in-stressed-pacu-piaractus-mesopotamicus
#5
Eduardo Pahor-Filho, Adriana Soliris Corredor Castillo, Nycolas Levy Pereira, Fabiana Pilarski, Elisabeth Criscuolo Urbinati
We analyzed the effects of levamisole on stress and the innate immune responses of pacu (Piaractus mesopotamicus). A total of 300 fish (180 ± 1.27 g) were fed a diet containing levamisole hydrochloride (LHC) for 15 days, then distributed into the following groups: T0 (control group); T1 (100), T2 (150), T3 (300) and T4 (500) mg kg-1 LHC (15 fish per group and four replicates per treatment). After this, fish (n = 8 per treatment) were exposed to air for three minutes to simulate stress conditions and were then challenged with the bacterium Aeromonas hydrophila to stimulate the immune system...
June 2017: Fish & Shellfish Immunology
https://www.readbyqxmd.com/read/27811836/recommendations-for-use-of-meningococcal-conjugate-vaccines-in-hiv-infected-persons-advisory-committee-on-immunization-practices-2016
#6
Jessica R MacNeil, Lorry G Rubin, Monica Patton, Ismael R Ortega-Sanchez, Stacey W Martin
At its June 2016 meeting, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of meningococcal conjugate vaccine (serogroups A, C, W, and Y; including MenACWY-D [Menactra, Sanofi Pasteur] or MenACWY-CRM [Menveo, GlaxoSmithKline]) for persons aged ≥2 months with human immunodeficiency virus (HIV) infection. ACIP has previously recommended routine vaccination of persons aged ≥2 months who have certain medical conditions that increase risk for meningococcal disease (1), including persons who have persistent (e...
November 4, 2016: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/27617501/c3-ch50-ratio-as-a-proposed-composite-marker-for-eculizumab-monitoring-in-atypical-hemolytic-uremic-syndrome-preliminary-results
#7
Kheir Eddine Kerboua, Fatma Haiba, Djamila Batouche
Treatment of atypical hemolytic uremic syndrome (aHUS) by the complement C5 inhibitor eculizumab (Soliris®) is highly effective but unfortunately, associated with an economic pressure on the health care systems even in high incomes countries. Despite spacing infusions having been proposed as the unique solution to minimize this economic impact, no reliable laboratory assays are available to tailor such therapy optimization. We aimed to propose and evaluate a complement composite marker for eculizumab efficacy monitoring in aHUS...
2017: Journal of Immunoassay & Immunochemistry
https://www.readbyqxmd.com/read/27573083/recommendations-for-serogroup-b-meningococcal-vaccine-for-persons-10-years-and-older
#8
REVIEW
(no author information available yet)
This policy statement provides recommendations for the prevention of serogroup B meningococcal disease through the use of 2 newly licensed serogroup B meningococcal vaccines: MenB-FHbp (Trumenba; Wyeth Pharmaceuticals, a subsidiary of Pfizer, Philadelphia, PA) and MenB-4C (Bexsero; Novartis Vaccines, Siena, Italy). Both vaccines are approved for use in persons 10 through 25 years of age. MenB-FHbp is licensed as a 2- or 3-dose series, and MenB-4C is licensed as a 2-dose series for all groups. Either vaccine is recommended for routine use in persons 10 years and older who are at increased risk of serogroup B meningococcal disease (category A recommendation)...
September 2016: Pediatrics
https://www.readbyqxmd.com/read/27414068/notes-from-the-field-meningococcal-disease-in-an-international-traveler-on-eculizumab-therapy-united-states-2015
#9
Allen O Applegate, Vanessa C Fong, Kara Tardivel, Susan A Lippold, Sheilah Zarate
On June 2, 2015, CDC was notified that a male airline passenger, aged 41 years, with a fever of 105.4°F, headache, nausea, photophobia, diarrhea, and vomiting, which began approximately 3 hours after departure, was arriving to San Francisco, California, on a flight from Frankfurt, Germany. His symptoms reportedly started with neck stiffness 1 day earlier. Upon arrival, the patient was immediately transported to a local hospital, where he was in septic shock, which was followed by multisystem organ failure...
July 15, 2016: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/26915814/off-label-use-of-the-expensive-orphan-drug-eculizumab-in-france-2009-2013-and-the-impact-of-literature-focus-on-the-transplantation-field
#10
Johann Castañeda-Sanabria, David Hajage, Melisande Le Jouan, Anne Perozziello, Florence Tubach
PURPOSE: The orphan drug eculizumab (Soliris ®) is one of the most expensive in the world and based on expenditures is classed among the highest in France, a scenario suggestive of off-label use. Given its pharmacological properties, it is likely to be used in organ transplantation. Our purposes were to describe the consumption trends of eculizumab for off-label indications overall and in the organ transplantation field and to assess the impact of publications on the latter use. METHODS: We carried out a temporal ecological study within the French national hospitalization database (PMSI)...
June 2016: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/26837283/the-clinical-potential-of-affibody-based-inhibitors-of-c5-for-therapeutic-complement-disruption
#11
EDITORIAL
Magnus M Berglund, Patrik Strömberg
No abstract text is available yet for this article.
2016: Expert Review of Proteomics
https://www.readbyqxmd.com/read/26034803/eculizumab-soliris-and-paroxysmal-nocturnal-haemoglobinuria-in-children-when-transfusions-are-too-frequent
#12
(no author information available yet)
Many uncertainties; assessment based on extrapolation of adult data.
May 2015: Prescrire International
https://www.readbyqxmd.com/read/25343125/current-treatment-of-atypical-hemolytic-uremic-syndrome
#13
REVIEW
Bernard S Kaplan, Rebecca L Ruebner, Joann M Spinale, Lawrence Copelovitch
Tremendous advances have been made in understanding the pathogenesis of atypical Hemolytic Uremic Syndrome (aHUS), an extremely rare disease. Insights into the molecular biology of aHUS resulted in rapid advances in treatment with eculizumab (Soliris(®), Alexion Pharmaceuticals Inc.). Historically, aHUS was associated with very high rates of mortality and morbidity. Prior therapies included plasma therapy and/or liver transplantation. Although often life saving, these were imperfect and had many complications...
May 2014: Intractable & Rare Diseases Research
https://www.readbyqxmd.com/read/24534133/diagnosis-and-management-of-complement-mediated-thrombotic-microangiopathies
#14
REVIEW
Spero R Cataland, Haifeng M Wu
Historically, attempts were made to differentiate acquired thrombotic thrombocytopenic purpura (TTP) from atypical hemolytic uremic syndrome (aHUS) based upon the age at presentation and the presence of neurologic or renal injury. Although these means of differentiating acquired TTP from aHUS have now been demonstrated to be inaccurate, there were no clinical consequences as the treatment for both disorders remained plasma exchange therapy (PEX). With the regulatory approval and remarkable efficacy of eculizumab (Soliris) for the treatment of aHUS, the accurate and timely differentiation of acquired TTP from aHUS now has real clinical consequences...
March 2014: Blood Reviews
https://www.readbyqxmd.com/read/24331206/learnings-from-over-25-years-of-pnh-experience-the-era-of-targeted-complement-inhibition
#15
REVIEW
Ellen Heitlinger
Paroxysmal nocturnal haemoglobinuria (PNH) is a progressive and life-threatening disease that causes thrombosis, end organ damage and impaired quality of life. Chronic uncontrolled complement activation leads to chronic haemolysis, causing progressive morbidities and early mortality. Hence, early diagnosis is essential for improved patient management and prognosis. Eculizumab (SOLIRIS®) specifically inhibits chronic, uncontrolled complement activation and is the first-in-class, humanised, monoclonal antibody targeting C5 within the terminal complement pathway...
December 2013: Blood Reviews
https://www.readbyqxmd.com/read/24249647/eculizumab-a-review-of-its-use-in-atypical-haemolytic-uraemic-syndrome
#16
REVIEW
Gillian M Keating
The recombinant humanized monoclonal antibody eculizumab (Soliris(®)) is a complement inhibitor that is indicated for use in the treatment of atypical haemolytic uraemic syndrome (aHUS). This article reviews the clinical efficacy and tolerability of eculizumab in the treatment of patients with aHUS, as well as summarizing its pharmacological properties. Intravenous eculizumab inhibited complement-mediated thrombotic microangiopathy in patients aged ≥12 years with aHUS, according to the results of two noncomparative, multinational, 26-week, phase II trials...
December 2013: Drugs
https://www.readbyqxmd.com/read/23917586/perisurgical-induction-of-eculizumab-in-a-patient-with-paroxysmal-nocturnal-hemoglobinuria-its-inhibition-of-surgery-triggered-hemolysis-and-the-consequence-of-subsequent-discontinuation
#17
Naoki Kurita, Naoshi Obara, Kuniyoshi Fukuda, Hidekazu Nishikii, Shoko Sato, Satoshi Inagawa, Tomohiro Kurokawa, Yohei Owada, Haruhiko Ninomiya, Shigeru Chiba
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by complement (C')-induced lysis of PNH red blood cells (RBCs), which are deficient in the expression of CD55 and CD59. Surgery is one of the major clinical situations that trigger hemolytic attack and thrombosis in PNH. We describe here a case of 64-year-old man with classic PNH complicated by early-stage gastric cancer requiring distal gastrectomy under general anesthesia. We administered humanized monoclonal anti-C5 antibody (eculizumab; Soliris) for a limited period (600 mg, once a week × four times) perisurgically...
September 2013: Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis
https://www.readbyqxmd.com/read/23456264/successful-anticoagulant-therapy-for-two-pregnant-pnh-patients-and-prospects-for-the-eculizumab-era
#18
REVIEW
Yasuyoshi Morita, Jun-ichi Nishimura, Takahiro Shimada, Hirokazu Tanaka, Kentaro Serizawa, Yasuhiro Taniguchi, Mitsuhiro Tsuritani, Yuzuru Kanakura, Itaru Matsumura
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired stem cell disorder characterized by intravascular hemolysis and thrombosis. The most serious complication is thrombosis, the risk of which is augmented by the hyper-coagulable state that occurs during pregnancy; despite this risk, however, young female PNH patients often desire to have a baby. We recently experienced two successful deliveries in PNH patients, who were treated with anticoagulant therapy during their pregnancies. Meanwhile, given the potential benefit of eculizumab (Soliris), a humanized monoclonal antibody against C5, in reducing thrombosis and hemolysis, it represents a promising therapeutic option for the treatment of pregnant PNH patients in combination with, or in replacement of, anticoagulant therapy...
April 2013: International Journal of Hematology
https://www.readbyqxmd.com/read/22350448/eculizumab-a-guide-to-its-use-in-paroxysmal-nocturnal-hemoglobinuria
#19
Gillian M Keating, Katherine A Lyseng-Williamson, Kate McKeage
The targeted terminal complement inhibitor eculizumab (Soliris) reduces intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), as well as stabilizing hemoglobin levels, improving fatigue and health-related quality of life, and reducing the requirement for packed red cell transfusions. Eculizumab is generally well tolerated in patients with PNH, although the risk of Neisseria meningitidis infection is increased with eculizumab, meaning that patients must be vaccinated.
April 1, 2012: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/21693335/eculizumab-for-the-treatment-of-de-novo-thrombotic-microangiopathy-post-simultaneous-pancreas-kidney-transplantation-a-case-report
#20
S Chandran, L Baxter-Lowe, J L Olson, S J Tomlanovich, A Webber
A 34-year-old female recipient of a simultaneous pancreas-kidney transplant presented 7 days posttransplant with acute renal allograft dysfunction, thrombocytopenia, and microangiopathic hemolytic anemia. Renal biopsy revealed acute antibody-mediated rejection (AMR) and acute thrombotic microangiopathy (TMA). Clinical and laboratory manifestations, which had only partly responded to treatment with daily plasma exchange and intravenous immunoglobulin, resolved rapidly and completely to eculizumab (Soliris, Alexion Pharmaceuticals, Inc...
June 2011: Transplantation Proceedings
keyword
keyword
16036
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"